$IMUX
Immunic Inc

2019 Q3 Form 10-Q Financial Statement

#000128077619000051 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.080M $8.980M $4.260M
YoY Change -15.45% 110.8% 56.62%
% of Gross Profit
Research & Development $7.102M $6.029M $2.157M
YoY Change 403.69% 179.51% -78.07%
% of Gross Profit
Depreciation & Amortization $9.000K $24.00K $200.0K
YoY Change -95.59% -88.0% -12.66%
% of Gross Profit
Operating Expenses $9.177M $15.01M $2.670M
YoY Change 408.42% 462.06% -78.72%
Operating Profit -$9.177M -$15.01M -$2.670M
YoY Change 408.42% 462.06% -78.72%
Interest Expense $60.00K $30.00K $160.0K
YoY Change -45.45% -81.25% -5.88%
% of Operating Profit
Other Income/Expense, Net $962.0K $293.0K $0.00
YoY Change 11925.0% -100.0%
Pretax Income -$8.220M -$14.71M -$12.68M
YoY Change -31.16% 16.01% 2.18%
Income Tax
% Of Pretax Income
Net Earnings -$8.215M -$14.71M -$2.670M
YoY Change 357.15% 451.09% -78.48%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$820.4K -$1.521M -$11.96M
COMMON SHARES
Basic Shares Outstanding 10.09M shares 42.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.50M $36.10M $31.10M
YoY Change 71.35% 16.08% -59.19%
Cash & Equivalents $30.50M $36.12M $31.12M
Short-Term Investments
Other Short-Term Assets $4.100M $2.500M $1.500M
YoY Change 215.38% 66.67% -21.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $34.52M $39.49M $32.65M
YoY Change 81.1% 20.98% -58.18%
LONG-TERM ASSETS
Property, Plant & Equipment $44.00K $43.00K $2.059M
YoY Change -95.06% -97.91% -15.27%
Goodwill $32.97M $32.97M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $97.00K
YoY Change -46.7%
Total Long-Term Assets $33.09M $33.08M $2.156M
YoY Change 3469.04% 1434.37% -17.46%
TOTAL ASSETS
Total Short-Term Assets $34.52M $39.49M $32.65M
Total Long-Term Assets $33.09M $33.08M $2.156M
Total Assets $67.60M $72.57M $34.80M
YoY Change 238.22% 108.54% -56.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.718M $1.462M $1.075M
YoY Change 228.74% 36.0% -0.09%
Accrued Expenses $3.236M $1.586M $7.185M
YoY Change -28.91% -77.93% 16.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.036M $3.122M $8.299M
YoY Change 23.63% -62.38% 13.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.00K $41.00K $0.00
YoY Change
Total Long-Term Liabilities $41.00K $41.00K $49.00K
YoY Change -8.89% -16.33% 6.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.036M $3.122M $8.299M
Total Long-Term Liabilities $41.00K $41.00K $49.00K
Total Liabilities $7.077M $3.163M $8.348M
YoY Change 23.38% -62.11% 13.76%
SHAREHOLDERS EQUITY
Retained Earnings -$52.00M -$44.01M -$323.0M
YoY Change -84.48% -86.38% 20.13%
Common Stock $1.000K $1.500M $4.000K
YoY Change -75.0% 37400.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $60.53M $69.41M -$18.97M
YoY Change
Total Liabilities & Shareholders Equity $67.60M $72.57M $34.80M
YoY Change 238.22% 108.54% -56.86%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$8.215M -$14.71M -$2.670M
YoY Change 357.15% 451.09% -78.48%
Depreciation, Depletion And Amortization $9.000K $24.00K $200.0K
YoY Change -95.59% -88.0% -12.66%
Cash From Operating Activities -$5.980M -$10.98M -$12.36M
YoY Change -54.28% -11.17% 21.77%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K -$180.0K
YoY Change -96.3% -94.44% 28.57%
Acquisitions
YoY Change
Other Investing Activities $1.250M $9.340M $0.00
YoY Change -100.0%
Cash From Investing Activities $1.240M $9.330M -$180.0K
YoY Change -559.26% -5283.33% 38.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 220.0K 9.440M 10.00K
YoY Change 1000.0% 94300.0% -104.76%
NET CHANGE
Cash From Operating Activities -5.980M -10.98M -12.36M
Cash From Investing Activities 1.240M 9.330M -180.0K
Cash From Financing Activities 220.0K 9.440M 10.00K
Net Change In Cash -4.520M 7.790M -12.53M
YoY Change -66.09% -162.17% 19.45%
FREE CASH FLOW
Cash From Operating Activities -$5.980M -$10.98M -$12.36M
Capital Expenditures -$10.00K -$10.00K -$180.0K
Free Cash Flow -$5.970M -$10.97M -$12.18M
YoY Change -53.4% -9.93% 21.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10093454 shares
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
IMMUNIC, INC.
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1400000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1462000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
416000 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1586000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-819000 USD
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-722000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
56000 USD
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114137000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
61000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5300000 EUR
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7627000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23049000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-32006000 USD
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1500000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3398000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.82
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5633000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14370000 USD
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18930000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-19567000 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
0 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
0 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13072000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
529000 USD
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2019Q2 us-gaap Contractual Obligation
ContractualObligation
1400000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.60
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-722000 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
37193000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36121000 USD
CY2018Q2 us-gaap Depreciation
Depreciation
4000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-700000 USD
us-gaap Depreciation
Depreciation
7000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4504000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12131000 USD
CY2019Q2 us-gaap Depreciation
Depreciation
24000 USD
us-gaap Depreciation
Depreciation
29000 USD
CY2019Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3719.6
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
237479 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000 USD
CY2018 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
846953 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
846953 shares
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13072000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36121000 USD
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9986399 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000 USD
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.15
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120070 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
846953 shares
CY2018Q4 us-gaap Assets
Assets
13371000 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1500000 USD
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9986399 shares
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1423000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-47000 USD
CY2019Q2 us-gaap Assets
Assets
72574000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
13331000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
39493000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1463000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-61000 USD
CY2018 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-55000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-297000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
0 USD
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
296000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
26000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
513000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1017000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8978000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10285000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1862000 USD
us-gaap Interest Paid Net
InterestPaidNet
1000 USD
us-gaap Interest Paid Net
InterestPaidNet
34000 USD
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
608000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
61000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
32970000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
-1000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
34000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
34000 USD
CY2019Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
41000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12564000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
73000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
29000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
29000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
15000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000 USD
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2018Q4 us-gaap Liabilities
Liabilities
1920000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
3163000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13371000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72574000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1920000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3122000 USD
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
29965000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-7000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9324000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4208000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16304000 USD
vtl Cash Acquired In Connection With Reverse Acquisition
CashAcquiredInConnectionWithReverseAcquisition
0 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2263000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2670000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4933000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4313000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14714000 USD
us-gaap Net Income Loss
NetIncomeLoss
-19027000 USD
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
39400000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
293000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
642000 USD
CY2018Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 USD
CY2018Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 USD
CY2019Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
920000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
2670000 USD
us-gaap Operating Expenses
OperatingExpenses
4957000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
15007000 USD
us-gaap Operating Expenses
OperatingExpenses
19669000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2670000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4957000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15007000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-19669000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
66000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
206000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000 USD
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
344000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
97000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
28000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-728000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-247000 USD
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
378000 USD
CY2018Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-728000 USD
vtl Cash Acquired In Connection With Reverse Acquisition
CashAcquiredInConnectionWithReverseAcquisition
8151000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000 USD
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
344000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
104000 USD
CY2019Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
259000 USD
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
259000 USD
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2452000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29965000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
12564000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2019Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
58400000 EUR
CY2019Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
67200000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
40000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1150000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43000 USD
CY2019Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
72000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2157000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3940000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6029000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9384000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24978000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44005000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5983000 USD
CY2019Q2 us-gaap Share Price
SharePrice
12.87
CY2018Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
460336 shares
CY2019Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
39400000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
37193000 USD
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9669129 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5282412 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-13337000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-15572000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-18970000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-25741000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-9770000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
69411000 USD
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.025
CY2018Q2 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2019Q2 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
846953 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
846953 shares
CY2018Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
210000 USD
CY2019Q2 vtl Accrued Clinical Costs
AccruedClinicalCosts
912000 USD
CY2016Q2 vtl Asset Purchase Agreement Royalties As Percent Of Aggregated Net Sales
AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
0.044
CY2018Q2 vtl Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
200000000 USD
CY2018Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
60000000 USD
CY2018Q2 vtl Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders
MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
2500000 shares
CY2018Q2 vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
9000 USD
vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
19000 USD
CY2019Q2 vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
43000 USD
vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
55000 USD
CY2019Q2 vtl Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.06
CY2019Q1 vtl Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.06
vtl Payment For Contingent Consideration Liability Stock
PaymentForContingentConsiderationLiabilityStock
0 USD
vtl Payment For Contingent Consideration Liability Stock
PaymentForContingentConsiderationLiabilityStock
1540000 USD
vtl Shelf Registration Agreement Commission Percent Of Gross Proceeds On Sale Of Common Stock
ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
0.030
CY2019Q1 vtl Stock Subscription Not Yet Issued
StockSubscriptionNotYetIssued
20531000 USD
CY2019Q2 vtl Stock Subscription Not Yet Issued
StockSubscriptionNotYetIssued
-20531000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with US GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, share-based compensation and notes related to contractual obligations. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-19-000051-index-headers.html Edgar Link pending
0001280776-19-000051-index.html Edgar Link pending
0001280776-19-000051.txt Edgar Link pending
0001280776-19-000051-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imux-063019xexhibit311.htm Edgar Link pending
imux-063019xexhibit312.htm Edgar Link pending
imux-063019xexhibit321.htm Edgar Link pending
imux-063019xexhibit322.htm Edgar Link pending
imux-63019x10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-20190630.xml Edgar Link completed
vtl-20190630.xsd Edgar Link pending
vtl-20190630_cal.xml Edgar Link unprocessable
vtl-20190630_def.xml Edgar Link unprocessable
vtl-20190630_lab.xml Edgar Link unprocessable
vtl-20190630_pre.xml Edgar Link unprocessable